en
Scientific article
Open access
English

Validation of a commercially available SARS-CoV-2 serological immunoassay

Publication date2020
Abstract

Objectives: To validate the diagnostic accuracy of a Euroimmun SARS-CoV-2 IgG and IgA immunoassay for COVID-19. Methods: In this unmatched (1:2) case-control validation study, we used sera of 181 laboratory-confirmed SARS-CoV-2 cases and 326 controls collected before SARS-CoV-2 emergence. Diagnostic accuracy of the immunoassay was assessed against a whole spike protein-based recombinant immunofluorescence assay (rIFA) by receiver operating characteristic (ROC) analyses. Discrepant cases between ELISA and rIFA were further tested by pseudo-neutralization assay.

Keywords
  • COVID-19
  • ELISA
  • Pseudovirus neutralisation assay
  • Recombinant immunofluorescence assay
  • SARS-CoV-2
  • Serological Assays
  • Serological testing strategy
Citation (ISO format)
MEYER, Benjamin et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. In: Clinical Microbiology and Infection, 2020. doi: 10.1016/j.cmi.2020.06.024
Main files (1)
Article (Accepted version)
accessLevelPublic
Secondary files (1)
Identifiers
ISSN of the journal1198-743X
379views
185downloads

Technical informations

Creation07/10/2020 10:34:00 AM
First validation07/10/2020 10:34:00 AM
Update time03/15/2023 10:18:44 PM
Status update03/15/2023 10:18:43 PM
Last indexation01/17/2024 10:25:38 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack